Longeveron Inc. Common Stock
LGVNLongeveron Inc. (LGVN) is a biotechnology company focused on developing regenerative medicine therapies, particularly using cellular and molecular approaches to address aging-related diseases and chronic conditions. The company emphasizes treatments derived from proprietary mesenchymal stem cell technology and other biologics to promote tissue repair and restore health.
Company News
The longevity biotech market is expanding rapidly, projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034. Multiple companies are advancing cell and gene therapies targeting age-related diseases: Lineage Cell Therapeutics is developing islet therapy for Type 1 diabetes, Ocugen reported 46% lesion reduction in age-related macular de...
Avaà Bio announced it has initiated manufacturing of a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein, a key anti-aging protein that naturally declines by 50% after age 40. The milestone represents a transition from research to production infrastructure for their Klothonova anti-aging platform using Cell-in...
The global cell therapy market is projected to surpass $8.2 billion in 2026, with CAR T-cell therapy expanding at 18% annually. Several companies are advancing manufacturing milestones and clinical breakthroughs: Avaà Bio initiated Master Cell Bank production for α-Klotho anti-aging therapy; FibroBiologics secured a patent for fibroblast cell t...
Longeveron Inc. completed a public offering of 5,882,354 Class A common stock and short-term warrants, raising approximately $5 million, with potential additional proceeds of $12.5 million from warrant exercises. The company plans to use funds for clinical development of laromestrocel targeting various medical conditions.
Longeveron presented positive long-term survival data for its Lomecel-B treatment in patients with Hypoplastic Left Heart Syndrome (HLHS). The data showed 100% 5-year survival and transplant-free rates, outperforming historical data. The findings support the potential of Lomecel-B as an adjunct therapy to improve outcomes for HLHS patients.
